Pacira CMO reports routine tax share withholding

Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a routine tax-related share disposition.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a routine tax-related share disposition. On the reported date, 4,728 shares of common stock were withheld by the company to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin directly holds 218,912.175 shares of Pacira BioSciences common stock. This event reflects tax withholding rather than an open-market sale or purchase.

Insider Trade Summary

Exercise Price or Tax Liability: 4,728 shares

Exercise Price or Tax Liability 1 txn

Insider SLONIN JONATHAN

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	4,728	$22.32	$106K

Holdings After Transaction: Common Stock — 218,912.175 shares (Direct)

Footnotes (1)

F1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Key Figures

Shares withheld for taxes: 4,728 shares Implied withholding price: $22.32 per share Shares held after transaction: 218,912.175 shares

3 metrics

Shares withheld for taxes 4,728 shares Withheld to cover tax obligations on RSU vesting

Implied withholding price $22.32 per share Value used for tax-withholding disposition

Shares held after transaction 218,912.175 shares Direct common stock holdings after withholding

Key Terms

restricted stock unit, tax withholding obligations, tax-withholding disposition

3 terms

restricted stock unit financial

"upon vesting of a restricted stock unit award"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

tax withholding obligations financial

"to cover tax withholding obligations upon vesting"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pacira BioSciences (PCRX) report for Jonathan Slonin?

Pacira BioSciences reported that Chief Medical Officer Jonathan Slonin had 4,728 common shares withheld. These shares were retained by the company to satisfy tax withholding obligations when a restricted stock unit award vested, rather than being sold on the open market.

How many Pacira BioSciences (PCRX) shares were affected by tax withholding in this Form 4?

The Form 4 shows 4,728 Pacira BioSciences common shares were withheld. The issuer retained these shares to cover Jonathan Slonin’s tax obligations upon vesting of a restricted stock unit award, which is a standard compensation-related transaction.

How many Pacira BioSciences (PCRX) shares does Jonathan Slonin hold after this transaction?

Following the tax withholding event, Jonathan Slonin directly holds 218,912.175 Pacira BioSciences common shares. This figure reflects his remaining position after 4,728 shares were withheld by the issuer to satisfy tax obligations on a vesting restricted stock unit award.

Was the Pacira BioSciences (PCRX) insider transaction an open-market sale or purchase?

The reported transaction was not an open-market sale or purchase. Instead, 4,728 shares were withheld by Pacira BioSciences to cover tax withholding obligations tied to a vesting restricted stock unit award for Chief Medical Officer Jonathan Slonin.

What does the Form 4 tax-withholding disposition mean for Pacira BioSciences (PCRX) shareholders?

The tax-withholding disposition reflects routine administration of equity compensation. Pacira BioSciences withheld 4,728 shares from Jonathan Slonin upon RSU vesting to satisfy taxes, while he continues to hold 218,912.175 shares directly, indicating this is a standard compensation-related event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 05:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		F		4,728⁽¹⁾	D	$22.32	218,912.175	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR